GlassScriptPhysician profile
Christopher F Lobo
NPI 1073571949
$5,533.50
in general payments reported to CMS, 2019-2025
51 companies · $768 in 2025
The $768 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $830 · 2020: $585 · 2021: $708 · 2022: $912 · 2023: $854 · 2024: $876 · 2025: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,493 · Education: $5.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,493.44 |
| Education | $5.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $797.86 | 2019-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $755.24 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Celgene Corporation | $446.44 | 2019-2025 | Reblozyl, Opdualag |
| Merck Sharp & Dohme LLC | $383.84 | 2019-2025 | Keytruda |
| Pfizer INC. | $333.84 | 2019-2024 | |
| Daiichi Sankyo INC. | $207.20 | 2021-2025 | Enhertu |
| Astellas Pharma US INC | $201.36 | 2019-2025 | Xospata, Padcev, Vyloy |
| Abbvie INC. | $173.26 | 2019-2025 | |
| Beigene USA, INC. | $142.79 | 2023-2024 | Brukinsa, Tevimbra |
| Novartis Pharmaceuticals Corporation | $137.02 | 2019-2025 | |
| Array Biopharma INC | $131.13 | 2020-2025 | Braftovi, Lorbrena, Mektovi |
| Takeda Pharmaceuticals U.S.A., INC. | $125.92 | 2023-2025 | Fruzaqla, Ninlaro |
| Adamas Pharmaceuticals, INC. | $125.00 | 2020 | |
| Adaptive Biotechnologies Corporation | $117.82 | 2024 | Clonoseq |
| Regeneron Healthcare Solutions, INC. | $107.13 | 2019-2024 | Libtayo |
Show all 50 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lobo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.